A large pharmaceutical company was launching a potential blockbuster in the treatment of various forms of anemia.  We supported their evaluation of additional indications by gathering insights from a representative group of US payers.  We provided recommendations not only in how best to design a value message within the indication, but also in how their approval in this indication might be managed in the context of anemia overall.

A large pharmaceutical company had a well-known and profitable respiratory franchise.  As they prepared to launch a novel combination product, they asked for us to conduct a comprehensive pricing study, taking into account multiple stakeholders and the impact of the new product on the rest of their portfolio.

A clinical stage biotech company was building up commercial operations for a novel anti-epileptic.  They asked us to provide a snapshot of the reimbursement landscape they could expect, and to help them  price their product for optimal revenues and access.

A large pharmaceutical client was bringing an immuno-oncology franchise to market with very high expectations.  We worked with them to create positioning and branding for the entire franchise that was informative, compelling, and coordinated with the brand positioning of their leading compounds.

A professional and consumer nutritional company sought new opportunities for nutritional supplementation.  They identified COPD as an area of unmet need, but knew little about the disease and its treatment.  We mapped the patient pathway and facilitated two top level workshops to identify opportunities for them to pursue.

A large medtech company wanted to improve the effectiveness of a common orthopedic procedure in order to better position their products with payers.  We mapped out the patient pathway for the procedure and highlighted areas where they could partner with payers, patients, and providers to add value.

A biotechnology company had brought their lead compound successfully through Phase 2 trials for a very rare endocrine disorder.  We helped them understand how their target clinicians would react to the existing data, and how best to generate compelling endpoints and measurements going forward.

A large global pharmaceutical company had identified auto-immune disorders as key targets for their R&D organization.  We conducted a Multi-Variable Analysis of a range of auto-immune diseases to evaluate opportunities while remaining product agnostic.

A large pharmaceutical company in partnership with a leading biologics company were preparing for the launch of a blockbuster monoclonal antibody in immunology.  They had full development programs for two indications in place, but felt the compound could address a variety of additional indications.  We conducted a Multi-Variable Analysis to recommend disease areas that provided opportunity and fit with this biologic.

A biotechnology company was looking to develop compounds for acute myloid leukemia, but had limited internal resources to evaluate the market.  We conducted a Market Opportunity Map to identify unmet needs and enhance their early stage decision making.